Patents by Inventor Mark R. Hellberg

Mark R. Hellberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BICYCLIC HETEROARYL INHIBITORS OF PDE4
    Publication number: 20130045975
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Application
    Filed: February 10, 2012
    Publication date: February 21, 2013
    Applicant: KALYPSYS, INC.
    Inventors: Steven P. Govek, Clay Beauregard, Daniel A. Gamache, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau, David J. Thomas, John M. Yanni
  • BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA
    Publication number: 20120283260
    Abstract: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
    Type: Application
    Filed: July 24, 2012
    Publication date: November 8, 2012
    Applicants: ASTELLAS PHARMA INC., ALCON RESEARCH, LTD.
    Inventors: Keith D. Combrink, Suchismita Mohapatra, Mark R. Hellberg, Najam A. Sharif, Ganesh Prasanna, Iok-Hou Pang, Bryon Severns, Hwang-Hsing Chen, Abdelmoula Namil
  • Bradykinin receptor agonists and uses thereof to treat ocular hypertension and glaucoma
    Patent number: 8252793
    Abstract: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
    Type: Grant
    Filed: August 17, 2011
    Date of Patent: August 28, 2012
    Assignees: Alcon Research, Ltd., Astellas Pharma Inc.
    Inventors: Keith D. Combrink, Suchismita Mohapatra, Mark R. Hellberg, Najam A. Sharif, Ganesh Prasanna, Iok-Hou Pang, Bryon Severns, Hwang-Hsing Chen, Abdelmoula Namil
  • CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS
    Publication number: 20120115870
    Abstract: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
    Type: Application
    Filed: January 11, 2012
    Publication date: May 10, 2012
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Debra L. Fleenor, Iok-Hou Pang, Allan R. Shepard, Mark R. Hellberg, Peter G. Klimko, Abbot F. Clark
  • Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
    Patent number: 8138205
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of phosphodiesterase 4 (PDE4) for the treatment or prevention of inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: March 20, 2012
    Assignee: Kalypsys, Inc.
    Inventors: Steven P. Govek, Clay Beauregard, Daniel A. Gamache, Mark R. Hellberg, Stewart A. Noble, Andrew K. Shiau, David J. Thomas, John M. Yanni
  • BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA
    Publication number: 20120046285
    Abstract: The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
    Type: Application
    Filed: August 17, 2011
    Publication date: February 23, 2012
    Applicants: ASTELLAS PHARMA INC., ALCON RESEARCH, LTD.
    Inventors: Keith D. Combrink, Suchismita Mohapatra, Mark R. Hellberg, Najam A. Sharif, Ganesh Prasanna, Iok-Hou Pang, Bryon Severns, Hwang-Hsing Chen, Abdelmoula Namil
  • Superoxide dismutase mimics for the treatment of ocular disorders and diseases
    Patent number: 8067405
    Abstract: The use of SOD mimics, particularly Mn(III) salen SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.
    Type: Grant
    Filed: March 24, 2010
    Date of Patent: November 29, 2011
    Assignee: Novartis AG
    Inventors: Peter G. Klimko, Robert J. Collier, Jr., Mark R. Hellberg
  • METHOD OF ACCELERATING CORNEAL WOUND HEALING
    Publication number: 20110207809
    Abstract: The topical ophthalmic use of 5,6,7-trihydroxyheptanoic acid and analogs for the acceleration of corneal wound healing in humans, is disclosed.
    Type: Application
    Filed: February 25, 2011
    Publication date: August 25, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Eric C. Carlson, Daniel A. Gamache, Mark R. Hellberg, Peter G. Klimko, Kerry L. Markwardt, John M. Yanni
  • Superoxide dismutase mimics for the treatment of ocular disorders and diseases
    Patent number: 8003635
    Abstract: The use of SOD mimics particularly pentaazacycle Mn(II) complex SOD mimics, for the treatment of AMD, DR, and retinal edema is disclosed.
    Type: Grant
    Filed: April 23, 2010
    Date of Patent: August 23, 2011
    Assignee: Novartis AG
    Inventors: Peter G. Klimko, Robert J. Collier, Jr., Mark R. Hellberg
  • CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS
    Publication number: 20110160210
    Abstract: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.
    Type: Application
    Filed: March 8, 2011
    Publication date: June 30, 2011
    Applicant: ALCON, INC.
    Inventors: Debra L. Fleenor, Iok-Hou Pang, Allan R. Shapard, Mark R. Hellberg, Abbot F. Clark, Peter G. Klimko
  • METHOD OF TREATING DRY EYE DISORDERS AND UVEITIS
    Publication number: 20110130451
    Abstract: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis.
    Type: Application
    Filed: February 8, 2011
    Publication date: June 2, 2011
    Applicant: Alcon, Inc.
    Inventors: Peter G. Klimko, Mark R. Hellberg, Daniel A. Gamache
  • NOVEL NPR-B AGONISTS
    Publication number: 20110112038
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: September 23, 2010
    Publication date: May 12, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Mark R. Hellberg, Iok-Hou Pang
  • PAI-1 EXPRESSION AND ACTIVITY INHIBITORS FOR THE TREATMENT OF OCULAR DISORDERS
    Publication number: 20110105574
    Abstract: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 expression or PAI-1 activity. Another embodiment of the present invention is a method of treating a PAI-1-associated ocular disorder in a subject in need, comprising administering to the patient an effective amount of a composition comprising an agent that inhibits PAI-1 activity or expression.
    Type: Application
    Filed: January 14, 2011
    Publication date: May 5, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Debra L. Fleenor, Allan R. Shepard, Iok-Hou Pang, Mark R. Hellberg, Abbot F. Clark
  • STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA
    Publication number: 20110098314
    Abstract: The use of HMG-CoA reductase inhibitors (e.g., statins) to treat glaucoma, control intraocular pressure, preserve the trabecular meshwork, protect against ocular neurodegeneration and/or protect against glaucomatous retinopathy is described. The preferred HMG-CoA reductase inhibitors, which are statins having an RI value of 0.2 to 0.7 (e.g., pravastatin), are administered via topical application to the affected eye(s) of the patient.
    Type: Application
    Filed: November 8, 2010
    Publication date: April 28, 2011
    Applicant: ALCON, INC.
    Inventors: Mark R. Hellberg, Debra L. Fleenor, Allan R. Shepard, Iok-Hou Pang
  • Method of treating dry eye disorders and uveitis
    Patent number: 7923471
    Abstract: The topical use of 5,6,7-trihydroxyheptanoic acid and analogs are disclosed for the treatment of dry eye disorders and uveitis.
    Type: Grant
    Filed: November 7, 2005
    Date of Patent: April 12, 2011
    Assignee: Alcon, Inc.
    Inventors: Peter G. Klimko, Mark R. Hellberg, Daniel A. Gamache
  • 5,6,7-TRIHYDROXYHEPTANOIC ACID AND ANALOGS FOR THE TREATMENT OF OCULAR DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVE AND ANGIOGENIC RESPONSES
    Publication number: 20110082200
    Abstract: Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 7, 2011
    Applicant: ALCON, INC.
    Inventors: Peter G. KLIMKO, Mark R. HELLBERG, David P. BINGAMAN, Daviel A. GAMACHE
  • NOVEL NPR-B AGONISTS
    Publication number: 20110077381
    Abstract: Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D-amino acid residues connected to one another via peptide bonds.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 31, 2011
    Applicant: ALCON RESEARCH, LTD.
    Inventors: Frank Osterkamp, Heiko Hawlisch, Gerd Hummel, Tobias Knaute, Ulf Reimer, Ulrich Reineke, Uwe Richter, Bernadett Simon, Edgar Specker, Markus Woischnik, Mark R. Hellberg
  • 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases
    Patent number: 7906512
    Abstract: Methods for treating an allergic or inflammatory disease or other Syk-mediated disease or Syk-mediated condition characterized by administering a composition which contains a therapeutically effective amount of a 3,6-substituted imidazol[1,2-b]pyridazine compound.
    Type: Grant
    Filed: March 10, 2010
    Date of Patent: March 15, 2011
    Assignee: Alcon, Inc.
    Inventors: Mark R. Hellberg, Steven T. Miller, Andrew Rusinko
  • 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses
    Patent number: 7879905
    Abstract: Compositions containing 5,6,7-trihydroxyheptanoic acid and analogs and their use for treating posterior segment ocular diseases and diseases characterized by cellular hyperproliferation or angiogenesis, are disclosed.
    Type: Grant
    Filed: November 8, 2005
    Date of Patent: February 1, 2011
    Assignee: Alcon, Inc.
    Inventors: Peter G. Klimko, Mark R. Hellberg, David P. Bingaman, Daniel A. Gamache
  • Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
    Patent number: 7867999
    Abstract: Methods for using hydroxyamino- and amino-substituted pyridine analogs are disclosed herein to treat rho kinase-mediated diseases or rho kinase-mediated conditions, including controlling intraocular pressure and treating glaucoma, are disclosed. Ophthalmic pharmaceutical compositions useful in the treatment of eye diseases such as glaucoma, and additionally useful for controlling intraocular pressure, the compositions comprising an effective amount of hydroxyamino- and amino-substituted pyridine analogs, are disclosed herein.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: January 11, 2011
    Assignee: Alcon Research, Ltd.
    Inventors: Hwang-Hsing Chen, Najam A. Sharif, Mark R. Hellberg